Filariasis medical therapy

Filariasis Microchapters
Home
Patient Information
Overview
Historical Perspective
Classification
Pathophysiology
Causes
Differentiating Filariasis from other Diseases
Epidemiology and Demographics
Risk Factors
Screening
Natural History, Complications and Prognosis
Diagnosis
History and Symptoms
Physical Examination
Laboratory Findings
X Ray
CT Scan
MRI
Ultrasound
Other Imaging Findings
Other Diagnostic Studies
Treatment
Medical Therapy
Surgery
Primary Prevention
Secondary Prevention
Cost-Effectiveness of Therapy
Future or Investigational Therapies
Case Studies
Case #1
Filariasis medical therapy On the Web
Most recent articles
Most cited articles
Review articles
CME Programs
slides
Images
American Roentgen Ray Society Images of Filariasis medical therapy All Images X-rays Echo & Ultrasound CT Images MRI
Ongoing Trials at Clinical Trials.gov
US National Guidelines Clearinghouse
NICE Guidance
FDA on Filariasis medical therapy
on Filariasis medical therapy
Filariasis medical therapy in the news
Blogs on Filariasis medical therapy
Directions to Hospitals Treating Filariasis
Risk calculators and risk factors for Filariasis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammed Abdelwahed M.D[2]

Overview

The mainstay treatment for patients with filariasis is albendazole (a broad spectrum anthelmintic) combined with ivermectin. A combination of diethylcarbamazine (DEC) and albendazole is also effective. All of these treatments are microfilaricides; they have no effect on the adult worms.

Medical Therapy

Antimicrobial Regimen

• Filariasis

• 1. Lymphatic filariasis caused by Wuchereria bancrofti, Brugia malayi, Brugia timori

• Preferred regimen: Diethylcarbamazine 6 mg/kd/day PO tid for 12 days. Single dose of (DEC) has the same long-term effect in decreasing levels of microfilaria in blood as 12-day regimen. If patient is co-infected with onchocerciasis or loiasis DEC is contraindicated. DEC induces reversal of early lymphatic dysfunction in a patient with W.bancrofiti filariasis.
• Chronic cases:
  • Regular exercise and leg elevation during night increase lymph flow.
  • Physiotherapy may be effective in some cases.
  • Reconstructive surgery involving lymphatic-venous anastomoses have been attempted to improve lymphatic drainage, but the long-term benefit is still unclear.

• 2. Loa loa filariasis

• 2.1 Symptomatic loiasis with < 8,000 microfilariae/mL

• Preferred regimen: Diethylcarbamazine 8–10 mg/kd/day PO tid for 21 days.

• 2.2 Symptomatic loiasis, with < 8,000 microfilariae/mL and failed 2 rounds DEC

• Preferred regimen: Albendazole 200 mg PO bid for 21 days.

• 2.3 Symptomatic loiasis, with ≥ 8,000 microfilariae/ml to suppress microfilaremia prior to treatment with DEC

• Preferred regimen: Albendazole 200 mg PO bid for 21 days.

• 2.4 Symptomatic loiasis, with ≥ 8,000 microfilariae/mL

• Preferred regimen: Apheresis followed by Diethylcarbamazine.
• Note: Apheresis should be performed at an institution with experience in using this therapeutic modality for loiasis.

• 3. River blindness (onchocerciasis) caused by Onchocerca volvulus

• Preferred regimen: Ivermectin 150 μg/kg PO single dose, repeated every 6-12 mos until asymptomatic.
• Alternative regimen: Doxycycline 100 mg PO qd for 6 weeks, alone or followed by Ivermectin 150 μg/kg PO single dose.
• Note: Do NOT administer Diethylcarbamazine where onchocerciasis is endemic due to increased risk for severe local inflammation in patients with ocular microfilariae.

• 4. Mansonella ozzardi

• Preferred regimen: Ivermectin 200 μg/kg PO single dose.
• Note: Endosymbiotic Wolbachia are essential to filarial growth, development, embryogenesis and survival and represent an additional target for therapy. Doxycycline 100–200 mg PO qd for 6–8 weeks results in loss of Wolbachia and decrease in both micro- and macrofilariae.

• 5. Mansonella perstans

• Preferred regimen: Doxycycline 100–200 mg PO qd for 6–8 weeks.

• 6. Mansonella streptocerca

• Preferred regimen (1): Diethylcarbamazine 6 mg/kd/day PO tid for 12 days.
• Preferred regimen (2): Ivermectin 150 μg/kg PO single dose.

• 7. Tropical pulmonary eosinophilia caused by Wuchereria bancrofti

• Preferred regimen: Diethylcarbamazine 6 mg/kd/day PO tid for 12–21 days.